Tirzepatide Phase 2 Trial on Organ-Specific Aging Opens Enrollment

A clinical trial update dated October 30, 2026 reports new status for a study involving tirzepatide. The trial, registered as NCT07906041 and titled "Tirzepatide and Organ-specific Biological Aging," is listed as a Phase 2 study. Its current status is enrolling by invitation. This means participants are being recruited through direct invitation rather than open public enrollment. The registry entry does not include results, efficacy data, or safety findings at this stage. No outcome data, interim analyses, or conclusions have been reported for this trial as of the listed date. Tirzepatide remains an approved compound, and this trial represents an additional area of clinical investigation beyond its approved uses. The study is identified under ClinicalTrials.gov with the identifier NCT07906041, where further protocol details are posted. As with any enrolling trial, status may change as recruitment progresses and as the study moves through its planned phases. Readers interested in tirzepatide's broader development history, approved indications, and other ongoing research can consult the compound overview for additional context on how this trial fits into the wider picture.